Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
2
BDTX Quote, Financials, Valuation and Earnings
Last price:
$2.70
Seasonality move
:
-28.39%
Day range:
$2.48 - $2.72
52-week range:
$1.20 - $4.94
Dividend yield:
0%
P/E ratio:
7.47x
P/S ratio:
2.21x
P/B ratio:
1.22x
Volume:
2.5M
Avg. volume:
1.4M
1-year change:
10.16%
Market cap:
$154.4M
Revenue:
--
EPS (TTM):
$0.36
Analysts' Opinion
-
Consensus RatingBlack Diamond Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.25, Black Diamond Therapeutics, Inc. has an estimated upside of 241.33% from its current price of $2.71.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing -121.4% downside risk from its current price of $2.71.
Fair Value
-
According to the consensus of 7 analysts, Black Diamond Therapeutics, Inc. has 241.33% upside to fair value with a price target of $9.25 per share.
BDTX vs. S&P 500
-
Over the past 5 trading days, Black Diamond Therapeutics, Inc. has underperformed the S&P 500 by -28.39% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Black Diamond Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Black Diamond Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Black Diamond Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Black Diamond Therapeutics, Inc. has grown year-over-year earnings for 15 quarters straight. In the most recent quarter Black Diamond Therapeutics, Inc. reported earnings per share of -$0.15.
Enterprise value:
38.6M
EV / Invested capital:
0.26x
Price / LTM sales:
2.21x
EV / EBIT:
3.25x
EV / Revenue:
0.55x
PEG ratio (5yr expected):
--
EV / Free cash flow:
1.81x
Price / Operating cash flow:
7.24x
Enterprise value / EBITDA:
3.16x
Gross Profit (TTM):
$69.7M
Return On Assets:
14.13%
Net Income Margin (TTM):
30.71%
Return On Equity:
18.5%
Return On Invested Capital:
15.62%
Operating Margin:
77.9%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | $70M | -- | -- | |
| Gross Profit | -$3.3M | -$344K | $69.7M | -$86K | -$86K | |
| Operating Income | -$87.5M | -$81.4M | $11.9M | -$18.1M | -$11M | |
| EBITDA | -$84.2M | -$81M | $12.2M | -$18M | -$10.9M | |
| Diluted EPS | -$2.13 | -$1.36 | $0.36 | -$0.28 | -$0.15 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $241.5M | $151M | $147M | $115.5M | $139M | |
| Total Assets | $274.1M | $180.4M | $172.4M | $137.9M | $157.7M | |
| Current Liabilities | $26.4M | $21.1M | $15.1M | $20.8M | $15.5M | |
| Total Liabilities | $55.2M | $47.2M | $38.1M | $40.5M | $31.6M | |
| Total Equity | $218.9M | $133.2M | $134.3M | $97.4M | $126.2M | |
| Total Debt | $28.8M | $26M | $23M | $19.7M | $16M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$74.7M | -$61.2M | $21.3M | -$11.3M | -$7.9M | |
| Cash From Investing | $6.4M | $1.4M | -$14.2M | $2.2M | $8.6M | |
| Cash From Financing | $72M | $25.2M | $341K | -$252K | $134K | |
| Free Cash Flow | -$74.7M | -$61.2M | $21.3M | -$11.3M | -$7.9M | |
BDTX
Sector
Market Cap
$154.4M
$28.4M
Price % of 52-Week High
54.86%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
0.22%
-1.32%
1-Year Price Total Return
10.16%
-22.19%
Beta (5-Year)
3.331
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.49
200-day SMA
Buy
Level
$2.69
Bollinger Bands (100)
Sell
Level
2.83 - 3.97
Chaikin Money Flow
Sell
Level
-176.6M
20-day SMA
Sell
Level
$3.88
Relative Strength Index (RSI14)
Sell
Level
26.77
ADX Line
Sell
Level
20.2
Williams %R
Neutral
Level
-79.0179
50-day SMA
Sell
Level
$3.87
MACD (12, 26)
Sell
Level
-0.21
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
112.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.9644)
Sell
CA Score
(Annual)
Level (-1.9273)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (4.0062)
--
Piotroski F Score
(Annual)
Level (--)
Buy
Quality Ratio Score
Level (8)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type-mediated toxicities, and be brain-penetrant to treat central nervous system diseases. It is currently focused on advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.
Stock Forecast FAQ
In the current month, BDTX has received 6 Buy ratings 1 Hold ratings, and 0 Sell ratings. The BDTX average analyst price target in the past 3 months is $9.25.
-
Where Will Black Diamond Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Black Diamond Therapeutics, Inc. share price will rise to $9.25 per share over the next 12 months.
-
What Do Analysts Say About Black Diamond Therapeutics, Inc.?
Analysts are divided on their view about Black Diamond Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Black Diamond Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is Black Diamond Therapeutics, Inc.'s Price Target?
The price target for Black Diamond Therapeutics, Inc. over the next 1-year time period is forecast to be $9.25 according to 7 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is BDTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Black Diamond Therapeutics, Inc. is a Buy. 6 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BDTX?
You can purchase shares of Black Diamond Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Black Diamond Therapeutics, Inc. shares.
-
What Is The Black Diamond Therapeutics, Inc. Share Price Today?
Black Diamond Therapeutics, Inc. was last trading at $2.70 per share. This represents the most recent stock quote for Black Diamond Therapeutics, Inc.. Yesterday, Black Diamond Therapeutics, Inc. closed at $2.71 per share.
-
How To Buy Black Diamond Therapeutics, Inc. Stock Online?
In order to purchase Black Diamond Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BDTX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BDTX
Sector
P/E ratio
7.47x
23.66x
PEG ratio
--
-0.01x
P/B ratio
1.22x
1.84x
Price / LTM sales
2.21x
1.60x
Growth Metrics
BDTX
Sector
Revenue growth
--
4.85%
Earnings growth
45.77%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.23
-$0.20
Profitability
BDTX
Sector
Profitability FY 2024
-$343K
$3.6M
Return on invested capital
15.62%
-30.98%
Return on assets
14.13%
-27.62%
Return on equity
18.5%
-36.69%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Feb
5
Balance Sheet
BDTX
Sector
Total cash
$135.5M
$27.2M
Short term investments
$62.1M
$25.7M
Total assets
$122.6M
$79.9M
Long term debt
$16M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
39
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
38
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
